Horizon Pharma sees FY19 revenue $1.26B-$1.28B, consensus $1.24B

The company now expects full-year 2019 net sales of $1.26 billion to $1.28 billion, an increase from the previous guidance range of $1.23 billion to $1.25 billion. Full-year 2019 adjusted EBITDA is now expected to be $450 million to $465 million, an increase from the previous guidance range of $440 million to $455 million, while also increasing investment in the potential U.S. launch of teprotumumab following Phase 3 trial results.
https://thefly.com/landingPageNews.php?id=2905571